<DOC>
	<DOCNO>NCT02320630</DOCNO>
	<brief_summary>This trial aim compare cost effective effect prevent recurrence different treatment TFP HCQ combine SSZ remittent RA .</brief_summary>
	<brief_title>Combination Therapy Prevents Relapse RA</brief_title>
	<detailed_description>patient divide 3groups : Group A : TFP+MTX ( week0-week60 ) Group B : TFP+MTX+HCQ+SSZ ( week0-week12 ) MTX+HCQ+SSZ ( week13-week60 ) Group C : TFP+MTX ( week0-week12 ) MTX ( week13-week60 )</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Disease Attributes</mesh_term>
	<criteria>Fulfill 2010 EULAR/ACR RA dignose criterion Age1870 year old Have teated regularly 3 month Disease duration &gt; 6months DAS28 &gt; 3.2 Received surgical operation 8 week Received biological agent ( eg . rituximab , antiTNF agent , antiIL6 agent ) 6 month ; Injection steroid 4 week Coexisting CTD except SS With severe control cardiac vescular disease , neurological disease , pulmonary disease ( include COPD ILD ) , renal disease , liver disease , endocrine disease Gastric Intestinal Disease With controled disease include asthma , IBD psoriasis need oral injection steroid Active infection T &gt; 38℃ . Patients need admit hospital biotics injection 4 week need oral biotics 2 week Malignant history . Serum creatinine &gt; 130 µmol/L AST/ALT high 2 time upper level platelet count &lt; 100 x 109/L，or white blood count &lt; 3 x 109/L Interstitail lung disease : Chest X Ray Hands X Ray ACR radiology stag show IV stage RA Pregnancy plan pregnant 2 year suckle period woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>